Web Extra: Bad Side Effects


It appears results of a recent Alzheimer’s study aren’t as positive as investors had first thought.

Shares of Wyeth and Elan sold-off after analysts said the new data on bapineuzumab, released Tuesday, presents significant safety issues and makes it less likely the drug will reach the market.

Questions regarding bapineuzumab are likely to linger until the arrival of more data, which isn't expected until 2010.

How should you trade?

This content is only available online - you won't find these trades on TV.

Looking for more trades? Click here to check out the Fast Money Final Trades?

Got something to say? Send us an e-mail at fastmoney-web@cnbc.com and your comment might be posted on the Rapid Recap! If you'd prefer to make a comment but not have it published on our website send your message to fastmoney@cnbc.com.

Trader disclosure: On July 30, 2008, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Najarian Owns (AAPL), (TSO); Najarian Owns (CSCO) Calls, (EMC) Calls, (XLY) Calls, (SU) Calls; Macke Owns (WMT), (MSFT), (COST), (ATVID), (DIS), (EMC); Adami Owns (C), (GS), (INTC), (NUE), (AGU), (MSFT), (BTU); Finerman Owns (GS); Finerman's Firm And Finerman Own (C) Leaps; Finerman's Firm Owns (FLS), (MO), (NOK), (PM), (RAI), (SUN), (TSO), (VLO), (RIG), (MCC); Finerman's Firm Is Short (SPG), (KIM), (XLF), (BBT), (IYR), (IWM), (MDY), (SPY), (IJR)